To register please send an email to alicia@onenucleus.com

Attendance at this event is complimentary. 

This event is primarily focused on early-stage life science innovators, biotechs, companies in bioincubators and translational research groups with an interest in protein expression and approaches/tools to successfully scale.  Please note, all registrations are subject to the approval of the sponsor and registration cancelled if they are not considered to meet the above criteria. You will be informed if your registration has been cancelled within 2 working days of registering online for the event.

One Nucleus and Lonza are pleased to invite you to join us for a complimentary virtual symposium to gain insight from experts in the different approaches and techniques to successfully progress biotherapeutic candidates from discovery to the clinic. Enjoy updates on enhancements to new and established technologies enabling translational research. The symposium includes presentations from industry experts, local companies and technical specialists from Lonza.
 

Our networking breaks and virtual lunch offer the opportunity to speak with fellow scientists, presenters and Lonza specialists. You will also have the opportunity to book a virtual consultancy session with one of Lonza’s technical experts, which will take place after the symposium.
 

Agenda (Times are in GMT)

08.30 - 08.45  Welcome and symposium overview

Dr. Tony Jones, CEO, One Nucleus | Lonza representative

Moderator: Dr. Hari Kumar, Pharmaceutical Executive; Independent Board Member; former CEO Adheron Therapeutics

08.45 - 09.25  Keynote: Potent neutralisation of SARS-CoV-2 by nanobodies that block binding to ACE2

Professor Ray Owens, Head of Protein Production – UK (PPUK), Rosalind Franklin Institute,University of Oxford

09.25 - 09.50  Right first time: optimize and de-risk your early development journey

Dr. Yvette Stallwood | Head of Applied Protein Services, Lonza

09.50 - 10.15  Bispecific discovery: Where do we start and where are we going?

Dr. Ed McGowan, Director of Antibody Discovery & Development, Isogenica

10.15 - 10.30  Virtual coffee break - Networking tables with speakers

10.30 - 11.10  Approaches to maximize successful development of cell lines expressing a diverse range of proteins

Dr. Alison Porter, Head of Expression System Sciences, Lonza

11.10 - 11.35  The CB307 humabody journey: From molecule to medicine

Julia Pizzey, Director CMC Analytical Development, Crescendo Biologics

11.35 - 12.00  A step forward – combined strategies to enhance the performance of Pichia pastoris

Dr. Joachim Klein, Head of Strain Development and Cell Banking, Microbial Development Services, Lonza

12.00 - 12.40  Virtual networking lunch – Networking tables with speakers

12.40 - 13.00  AI-Augmented Drug Discovery
Murat Tunaboylu, CEO, Antiverse

13.00 - 13.20  Unlocking the next generation of antibody drug conjugate cancer therapeutics
Dr. Myriam Ouberai, CEO & Founder, Spirea

13.20 - 13.40  KnotBody technology: Antibody-like Modulators of Ion Channels by Fusing Venom-derived Peptides into Antibody CDR Loops

Dr. John McCafferty, CEO & Founder, Maxion Therapeutics

13.40 - 14.00  Closing remarks and close